Novo Nordisk Announces Ozempic Reduces Major Cardiovascular Events by 20% in SELECT Trial

Novo Nordisk today announced results from the SELECT cardiovascular outcomes trial showing that semaglutide 2.4 mg (Wegovy) reduced the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo in overweight or obese adults with established cardiovascular disease but without diabetes. The trial enrolled 17,604 patients and demonstrated a statistically significant reduction in the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. These results led to FDA approval of Wegovy for reducing cardiovascular risk in appropriate patients. This landmark trial establishes semaglutide as a cardiovascular risk reduction therapy beyond its weight loss benefits.